SCHEMBL7090853

SCHEMBL7090853

O=C(O)c1cnccc1-n1cccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
CYP46A1 Q9Y6A2 1/20 0.47
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.43
G6PD P11413 1/20 0.43
KDM4C Q9H3R0 5/20 0.42
KDM4D Q6B0I6 3/20 0.42
KDM6B O15054 2/20 0.42
KDM4A O75164 2/20 0.42
THRB P10828 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATR Q13535 1/20 0.39
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39
ACLY P53396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8174331 0.86 SIRT3 (0.47) LMNACYP46A1KDM4EALDH1A1KMT2A
SCHEMBL21816147 0.82 ALDH1A1 (0.48) LMNACYP46A1KDM4EALDH1A1KMT2A
SCHEMBL1339393 0.81 ALDH1A1 (0.50) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL1587001 0.77 HCRTR1 (0.49) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL30298688 0.76 CYP46A1 (0.46) LMNACYP46A1KDM4EALDH1A1KMT2A
SCHEMBL19480956 0.76 KDM4C (0.47) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL16655218 0.75 MYC (0.51) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL17007197 0.75 KCNN4 (0.52) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL9955483 0.75 HCRTR1 (0.46) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL30048018 0.75 KCNN4 (0.52) LMNAKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 US disclosed
US-20220315583-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 US disclosed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 EP disclosed
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 CN disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US disclosed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US disclosed
EP-1337251-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2003-08-27 EP disclosed
WO-2002102380-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885
US-20220315583-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP LMNA 1845/4885CYP46A1 451/4885KDM4E 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.